An observational study in T2DM (Type 2 Diabetes Mellitus) and Hypogonadism, sponsored by Besins Healthcare. Completed at 2 sites in Russian Federation. Open to male participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-06-20.
Sponsored by Besins Healthcare · Observational
Among 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Russian Federation.
Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation, this one is the 21st largest by enrollment of the 24 observational ones that give a count, is one of 19 that started in 2017, is one of 24 observational ones, and was the 247th registered.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 45 Years to 60 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
277 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 40 · Phase 3 173 · Phase 4 30
First in 2001; this study’s year is marked. 19 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 554 is above the median of 300 across 1,741 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 542 across the 253 interventional studies, 2,743 across the 24 observational. Of the 272 that completed or were terminated, 182 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
263 of 277 have an industry lead sponsor. The 10 most frequent:
Besins Healthcare is the lead sponsor of 2 studies on the registry; none are open to participants now.
Besins Healthcare has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to get data of prevalence of testosterone deficiency in patient with T2DM in Russian Federation
Clinical and Epidemiological Characteristics and Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus Under Routine Clinical Practice (DESTINY)
Men with T2DM aged between 45-60 years old
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Testosterone HSBG Hb1Ac LH
The prevalence of hypogonadism in patients with T2DM
The prevalence of hypogonadism in patients with T2DM
Time frame: 2017-2018
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Dec 2017 to primary completion in Feb 2019, 13 months.
Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 13 months is below that.
Counting every sponsor, half of 602 studies reached it within 32 months; a quarter within 17 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Besins Healthcare